Page last updated: 2024-11-06

1,2,3,4,6,7,8-heptachlorodibenzodioxin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2,3,4,6,7,8-heptachlorodibenzodioxin: contaminant of pentachlorophenol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID37270
CHEBI ID81505
SCHEMBL ID2879834
MeSH IDM0135535

Synonyms (28)

Synonym
1,2,3,4,6,7,8-heptachlorodibenzodioxin
1,2,3,4,6,7,8-heptachloro dibenzo-p-dioxin
brn 1630271
heptachlorodibenzo-p-dioxin
dibenzo-p-dioxin, 1,2,3,4,6,7,8-heptachloro-
ccris 9023
1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin
1,2,3,4,6,7,8-heptachlorodibenzo-para-dioxin
dibenzo(b,e)(1,4)dioxin, 1,2,3,4,6,7,8-heptachloro-
1,2,3,4,6,7,8-heptachlorodibenzo(b,e)(1,4)dioxin
hsdb 6474
35822-46-9
1,2,3,4,6,7,8-hpcdd
pcdd 73
C18103
FT-0669111
37871-00-4
unii-mm6333103r
mm6333103r ,
SCHEMBL2879834
heptachlorodibenzo-p-dioxin [hsdb]
CHEBI:81505
DTXSID1052034
1,2,3,4,6,7,8,-heptachlorodibenzodioxin
WCLNVRQZUKYVAI-UHFFFAOYSA-N
dibenzo[b,e][1,4]dioxin, heptachloro-
Q26841244
1,2,3,4,6,7,8-hepta-chlorodibenzo-p-dioxin

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Male Sprague-Dawley rats were treated with an LD20, LD50 and LD80 respectively, of tetra-, penta-, hexa-, hepta-CDD and a mixture of the four CDDs, all carrying chlorine substituents in the biologically crucial 2, 3, 7, and 8 positions."( Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part II: Structure-activity relationships with inhibition of hepatic phosphoenolpyruvate carboxykinase, pyruvate carboxylase, and gamma-glutamyl transpeptidase activities
Kettrup, A; Lebofsky, M; Rozman, K; Stahl, BU; Weber, LW, 1992
)
0.28
" The obtained LD50 value and (TEF) was for tetra-CDD 43 micrograms/kg (1), penta-CDD 206 micrograms/kg (0."( Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part I: Acute toxicity and toxic equivalency factors (TEFs).
Kettrup, A; Rozman, K; Stahl, BU, 1992
)
0.28
"007 as the toxic equivalency factor for HpCDD."( Subchronic (13-week) toxicity of heptachlorodibenzo-p-dioxin in male Sprague-Dawley rats.
Rozman, KK; Stahl, BU; Viluksela, M,
)
0.13
" The mixture was constituted such that each of the congeners contributed one fourth to total toxic equivalency."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. I. Design, general observations, hematology,and liver concentrations.
Birnbaum, LS; Kettrup, A; Rozman, KK; Schramm, KW; Stahl, BU; Viluksela, M, 1998
)
0.3
" This study supports the validity of the toxic equivalency factor (TEF) method and the notion of additive toxicity for CDDs as currently used in the risk assessment of these compounds."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.
Birnbaum, LS; Rozman, KK; Stahl, BU; Viluksela, M, 1998
)
0.3

Dosage Studied

ExcerptRelevanceReference
" By 8 days after dosing PEPCK activities were dose-dependently decreased after administration of all four CDDs and their mixture."( Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part II: Structure-activity relationships with inhibition of hepatic phosphoenolpyruvate carboxykinase, pyruvate carboxylase, and gamma-glutamyl transpeptidase activities
Kettrup, A; Lebofsky, M; Rozman, K; Stahl, BU; Weber, LW, 1992
)
0.28
" The dose-response to the mixture confirmed the hypothesis of strict additivity in the acute toxicity of the four CDD homologues."( Comparative toxicity of four chlorinated dibenzo-p-dioxins (CDDs) and their mixture. Part I: Acute toxicity and toxic equivalency factors (TEFs).
Kettrup, A; Rozman, K; Stahl, BU, 1992
)
0.28
" The dose-response effects of HpCDD on antibody responses to T-helper-cell-dependent (SRBC) and T-helper-cell-independent type 1 (TNP-LPS) and type 2 (DNP-Ficoll) antigens indicated that sensitivity to HpCDD-induced suppression directly correlated with the sensitivity of the response to T-cell regulation."( Mechanisms of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD)-induced humoral immune suppression: evidence of primary defect in T-cell regulation.
Brauner, JA; Kerkvliet, NI, 1987
)
0.27
" At the end of the 13-week dosing period half of the rats were scheduled for necropsy and the other half after another 13-week off-dose period."( Subchronic (13-week) toxicity of heptachlorodibenzo-p-dioxin in male Sprague-Dawley rats.
Rozman, KK; Stahl, BU; Viluksela, M,
)
0.13
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) in rats. Part I. Design, general observations, hematology, and liver concentrations.
Birnbaum, LS; Kettrup, A; Rozman, KK; Schramm, KW; Stahl, BU; Viluksela, M, 1997
)
0.3
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest assigned to an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) in rats. Part II. Biochemical effects.
Birnbaum, LS; Rozman, KK; Stahl, BU; Viluksela, M, 1997
)
0.3
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. I. Design, general observations, hematology,and liver concentrations.
Birnbaum, LS; Kettrup, A; Rozman, KK; Schramm, KW; Stahl, BU; Viluksela, M, 1998
)
0.3
" The dosing period was 13 weeks, after which half of the rats were necropsied and the rest provided with an off-dose period of another 13 weeks."( Subchronic/chronic toxicity of a mixture of four chlorinated dibenzo-p-dioxins in rats. II. Biochemical effects.
Birnbaum, LS; Rozman, KK; Stahl, BU; Viluksela, M, 1998
)
0.3
" Dose-response data at constant times illustrate the shifting of the dose-response curve towards a liminal value, which represents the necessary observation period for this effect."( Delayed acute toxicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD), after oral administration, Obeys Haber's rule of inhalation toxicology.
Rozman, KK, 1999
)
0.3
" The c x t = k product was independent of dosing regimen."( Chronic toxicity and carcinogenicity of 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin displays a distinct dose/time toxicity threshold (c x t = k) and a life-prolonging subthreshold effect.
Lebofsky, M; Pinson, DM; Rozman, KK, 2005
)
0.33
"There were striking dose-response relations between serum concentrations of six selected POPs and the prevalence of diabetes."( A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002.
Baker, BA; Jacobs, DR; Lee, DH; Lee, IK; Song, K; Steffes, M; Toscano, W, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
polychlorinated dibenzodioxineAny dibenzodioxine in which two or more hydrogens have been replaced by chlorines.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.56)18.7374
1990's15 (41.67)18.2507
2000's9 (25.00)29.6817
2010's9 (25.00)24.3611
2020's1 (2.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.65 (24.57)
Research Supply Index3.64 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (97.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]